FDA Inspection 1069420 — PAREXEL Early Phase Clinical Unit
The FDA completed an inspection of PAREXEL Early Phase Clinical Unit on Oct 17, 2018 in Baltimore, MD. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Oct 17, 2018
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Baltimore, MD (United States)
Additional Details
Clinical BA/BE